Gene mutation discovered for Early Onset PRA and gene test became commercially available through Optigen. In 2019 Mars partnered with Optigen to add Optigen’s DNA tests to their extensive array of DNA testing.
Funded Research
- Protective Role for Insulin-like Growth Factor 1 (IGF-1) in Canine Cognitive Dysfunction
- Combining Therapies to Improve Osteosarcoma Treatment
- Mitochondrial Dysfunction and mtDNA Mutations in Canine Hemangiosarcoma: Novel Biomarkers for Early Diagnosis and Personalized Therapy
- A combined sensor approach to examine volatile organic compounds as potential markers of canine hemangiosarcoma
- Engineering a monoclonal antibody therapy for canine mast cell tumors
- Canine Sports Medicine & Rehabilitation Residency Program-UPENN
- The prevalence of Heterobilharzia americana in Portuguese water dogs in the United States
- Building a Portuguese Water Dog Reference Genome to Unlock Breed-Specific Health Insights
- Studying Hemangiosarcoma Subtypes and Treatment Response
- Antiparasitic Treatment of Trypanosoma cruzi-infected Dogs Across Different Stages of Disease for Clinical Cardiac Improvements – the 100-dog Study